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Abstract 20 
 21 
Human and veterinary drug development addresses absorption, distribution, metabolism, 22 
elimination and toxicology (ADMET) of the Active Pharmaceutical Ingredient (API) in the 23 
target species.  Metabolism is an important factor in controlling circulating plasma and 24 
target tissue API concentrations and in generating metabolites which are more easily 25 
eliminated in bile, faeces and urine.  The essential purpose of xenobiotic metabolism is to 26 
convert lipid-soluble, non-polar and non-excretable chemicals into water soluble, polar 27 
molecules that are readily excreted.  Xenobiotic metabolism is classified into Phase I 28 
enzymatic reactions (which add or expose reactive functional groups on xenobiotic 29 
molecules), Phase II reactions (resulting in xenobiotic conjugation with large water-soluble, 30 
polar molecules) and Phase III cellular efflux transport processes.  The human-fish plasma 31 
model provides a useful approach to understanding the pharmacokinetics of APIs (eg 32 
diclofenac, ibuprofen and propranolol) in freshwater fish, where gill and liver metabolism of 33 
APIs have been shown to be of importance.  In contrast, wildlife species with low metabolic 34 
competency may exhibit zero order metabolic (pharmacokinetic) profiles and thus high API 35 
toxicity, as in the case of diclofenac and the dramatic decline of vulture populations across 36 
the Indian subcontinent.  A similar threat looms for African Cape Griffon vultures exposed to 37 
ketoprofen and meloxicam, recent studies indicating toxicity relates to zero order 38 
metabolism (suggesting P450 Phase I enzyme system or Phase II glucuronidation 39 
deficiencies).    While all aspects of ADMET are important in toxicity evaluations, these 40 
observations demonstrate the importance of methods for predicting API comparative 41 
metabolism as a central part of environmental risk assessment.  42 
 43 
[abstract word count = 249] 44 
 45 
Keywords:  medicines, environment, exposure, birds, fish, invertebrates  46 
 47 
1.0 Introduction 48 
 49 
Investigation of a pharmaceutical’s absorption, distribution, metabolism, elimination and 50 
toxicology (ADMET) play a central role in the pre-clinical and clinical safety assessment of 51 
human medicines [1].  Likewise, Active Pharmaceutical Ingredients (APIs) used in veterinary 52 
medicine are evaluated for their ADMET profile in the species of interest (for example, 53 
poultry or ruminants) [2, 3].  Metabolism of endogenous and exogenous molecules (eg plant 54 
toxins, pesticides and pharmaceuticals) is normally classified into Phase I enzymatic 55 
reactions (which add or expose –OH, -SH, -NH2 or -COOH functional groups on xenobiotics) 56 
and Phase II reactions (resulting in xenobiotic conjugation with large water-soluble, polar 57 
molecules).  Additionally, lipophilic xenobiotics, or their metabolites, can be pumped out of 58 
cells by specific transporter proteins and this efflux pump activity is often termed Phase III 59 
metabolism [4].  For approximately 5-7% of human drugs, Phase I metabolism may be 60 
responsible for conversion of a prodrug into the API [5].  More broadly, many Phase I 61 
biotransformations of lipophilic xenobiotics are carried out by microsomal monooxygenases, 62 
located in the endoplasmic reticulum of the liver and other organs [6].  The haem protein 63 
cytochrome P450 provides the active centre of these enzymes and has huge diversity, with 64 
37 cytochrome P450 families currently identified across many animal species [7].  It is 65 
hypothesized that the P450 superfamily has undergone repeated rounds of expansion by 66 
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genome duplication, whereby approximately one and a half billion years ago, the first 67 
expansion gave rise to the P450 families primarily involved in metabolising endogenous 68 
fatty acids, cholesterol and its derivatives (CYP4 and CYP11 families) which likely played a 69 
key role in maintaining the eukaryotic cell membrane integrity.  A later expansion of the 70 
P450 family nine hundred million years ago may have led to several endogenous steroid-71 
synthesizing cytochrome P450 lineages (including CYP19, CYP21 and CYP27 gene families; 72 
whereby the CYP21 family later diverged to give rise to the CYP1 and CYP2 families).  A final 73 
major expansion of several P450 families involved in xenobiotic metabolism (including CYP2, 74 
CYP3, CYP4 and CYP6), began about four hundred million years ago.  This most recent 75 
expansion is thought to have been driven by first the emergence of aquatic organisms onto 76 
land associated eating toxic plant allelochemicals (‘animal – plant warfare’), together with 77 
exposure of terrestrial organisms to hydrocarbon-based combustion products in the 78 
atmosphere [7-11].  79 
Much data exists on the metabolism of pharmaceuticals and other xenobiotics by the liver 80 
microsomes of mammals, birds and other species, with rates of microsomal oxidative 81 
metabolism determined across a range of vertebrates [2, 12, 13]. For example, Abass and 82 
colleagues [14] studied the metabolism of the insecticide benfuracarb by hepatic 83 
microsomes taken from seven mammalian species to investigate species-specific metabolic 84 
pathways. Benfuracarb is metabolised via sulphur-oxidation and nitrogen-sulphur bond 85 
cleavage (producing carbofuran which is further metabolised). Clearance rates for the seven 86 
species ranged from 1.4 (monkey) to 3.5 (rat), these differences being due to variability in 87 
CYP enzyme expression [14].  Among herbivorous and omnivorous mammals, there is a clear 88 
inverse correlation between the microsomal monooxygenase activity and body weight [15, 89 
16]. When hepatic monooxygenase activities are expressed in terms of body weight, much 90 
higher values are found in small rodents than in large mammals.  This observation is 91 
consistent with the concept of a co-evolutionary arms race between plants and herbivorous 92 
animals.  In this context, small mammals need to consume more food per unit body weight 93 
than do large ones in order to maintain body temperature due to their high surface area to 94 
volume ratios.  In contrast to the mammalian species studied by Walker and colleagues, the 95 
carnivorous (piscivorous or raptorial) species showed distinctly lower microsomal 96 
monooxygenase activities than did herbivorous or omnivorous birds (an observation also 97 
explicable in terms of ‘animal-plant arms race’ theory).  Predatory mammals (eg cats) and 98 
birds (eg raptors) eat very little, if any, plant material and therefore do not incur major 99 
pressure to drive the evolution of enzymes to metabolise plant toxins [16-19].  Interestingly, 100 
zebrafish (a widely used model in pharmaceutical research) show a dramatic increase in 101 
Phase I and II enzyme activity at the juvenile life stage in association with being fed plant 102 
based diets [20]. 103 
In contrast to terrestrial vertebrates, Phase I enzyme activities in fish are generally lower 104 
and there is only a weak correlation with body weight (whereas individual avian species 105 
show a correlation between body weight and hepatic microsomal monooxygenase activity 106 
across species) [12].  For fish, this has been explained on the grounds that they can excrete 107 
many xenobiotics by diffusion across gills into the large volume of ambient water and it has 108 
been argued that there has not been a strong pressure for the evolution of highly active 109 
detoxification enzymes as seen in mammals [13, 21].  A similar situation is thought to apply 110 
to aquatic invertebrates [22-24].  Nonetheless, as molecular and biochemical methods have 111 
advanced there growing evidence of both Phase I and II enzyme activity in fish [20, 25, 26] 112 
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and recent studies have addressed how dietary and trophic variables may affect enzyme 113 
activity in fish [27].  There are also a growing number of studies on the metabolism of 114 
pharmaceuticals in fish [28-38] but to far lesser extent invertebrates [39].  Veterinary 115 
pharmaceuticals have also been studied from a comparative metabolism perspective [40,41].  116 
Table 1 summarizes Phase I pathways of pharmaceutical and xenobiotic metabolism in 117 
mammals and other vertebrates, adapted from [42, 43] and updated with examples from 118 
the DrugBank on-line database http://www.drugbank.ca/ established by Wishart et al. [44]. 119 
 120 
Inset Table 1. 121 
 122 
2.0 In Vitro & In Silico Methods To Understand Comparative Metabolism 123 
 124 
In vitro systems are widely used for the investigation of xenobiotic metabolism in mammals 125 
[1], birds [45] and fish [36, 38].  Techniques include: (a) whole liver tissue slices which retain 126 
an accurate, structural framework of the liver; (b) whole isolated hepatocytes where the 127 
endoplasmic reticulum bound and cytosolic enzymes are present the structural integrity of 128 
liver network lost; (c) after centrifugation at 9000g, the S9 fraction supernatant from liver 129 
(or other tissue) homogenate contains both cytosolic (predominantly Phase II) and 130 
microsomal (predominantly Phase I) enzymes; and (d) microsomes comprising of 131 
endoplasmic reticulum bound enzymes that have been separated from cytosolic enzymes 132 
(P450 enzymes are concentrated in this subcellular fraction).  These methods are routinely 133 
used to determine the rate and extent of metabolism and mass-spectroscopic analysis of 134 
specific metabolites.  Results for clearance rates obtained from in vitro metabolism 135 
experiments can then be extrapolated to the in vivo situation using scaling factors (e.g. 136 
number of hepatocytes per liver; weight of microsomal protein per gram of liver, etc).  137 
Allometric methods can also be used to scale in vitro results between different species (used 138 
in drug development for scaling from preclinical species to man).  Where such values are 139 
known for wildlife species, this may allow for approximations between different species [15, 140 
16] and form a basis for models to aid in environmental risk assessment using fish [29,46,47], 141 
invertebrates [39] and plants [48].   142 
 143 
Novel in silico tools may also be useful to predict metabolism, this approach tending to 144 
focus on the semi-quantitative prediction of potential metabolites and identification of the 145 
specific enzymes responsible for the metabolism. Prediction of metabolic rates of drug 146 
metabolism remains a key challenge, especially with regard to identification of potential 147 
metabolites (which may be associated with specific toxicities) and identification of the 148 
enzymes responsible (combined with knowledge of different enzyme expression in different 149 
species). Kirchmair et al. [49] provide an overview of in silico tools for predicting key factors 150 
associated with metabolism (including sites of metabolism (SOM) within a molecule; 151 
potential metabolites; cytochrome P450 (CYP) binding affinity / inhibition; and prediction of 152 
CYP induction). Table 2 shows a representative software tool for each of these categories, 153 
however, many other tools are available [49]. 154 
 155 
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Insert Table 2. 156 
 157 
In silico tools have a number of potential advantages and provide complementary 158 
techniques to in vitro methods.  One area where information from both fields can be 159 
combined to build improved predictions is in physiologically-based pharmacokinetic (PBPK) 160 
modelling.  In this method an organism is divided into a sequence of physiological 161 
compartments (e.g. brain, liver, lungs, etc.). The models integrate compound-specific data 162 
(e.g. physico-chemical properties, such as log P, pKa or solubility, these values may be 163 
measured or predicted using in silico techniques) and species (or even subject)-specific data 164 
(e.g. physiological factors such as body or organ weights, volumes, or blood flow rates). 165 
Subject to validation, these models are potentially of high value in predicting concentration-166 
time profiles for pharmaceuticals in wildlife species [29,34,46]. Understanding inter-species 167 
differences in metabolism is essential for reliable PBPK models, especially in non-168 
mammalian species.  For example, Ohyama et al. [45] studied methoxychlor (MXC) 169 
metabolism in rat, mouse, Japanese quail and rainbow trout using liver slices.  Each species 170 
showed differences in metabolism, considered due to substrate specificity of CYP450s 171 
involved. MXC was metabolised to bis-OH-MXC which was then glucuronidated (with only 172 
rats producing the bis-OH-MXC 4 O-sulphate 4-O- glucuronide).  In mice and Japanese quail, 173 
mono-OH-MXC (and glucuronide conjugate) were the main metabolites and little bis-OH- 174 
MXC glucuronide was formed (dechlorinated mono-OH-MXC glucuronide was found only in 175 
mice).  Rainbow trout liver slices formed similar amounts of both metabolites.  In conclusion, 176 
rat and trout livers slices were able to metabolise both MXC and mono-OH MXC, whereas 177 
only MXC could be metabolised in mouse and Japanese quail [45].  178 
 179 
3.0 In Vivo Approaches in Studying Comparative Metabolism 180 
 181 
The overall effect a xenobiotic has on any organism is ultimately the result of it intrinsic 182 
activity and its concentration at the target site. Concentration at a given target site is 183 
determined by the ADME properties of the compound. The history of studying the time 184 
course and concentration of xenobiotics at different sites within the body has been 185 
developed predominantly within the pharmaceutical industry, with respect to drug effects 186 
on humans. However the techniques are applicable to diverse chemical space and across 187 
diverse species. In vivo measurements determining the pharmacokinetic profiles of 188 
xenobiotics in environmental species are largely unavailable, hence extrapolation and 189 
predictive models (combining in silico and in vitro methods) become essential tools in 190 
determining organ-level concentrations [50].  Metabolism is one of the key factors to 191 
consider when modelling the time course of a xenobiotic within an organism, not only as it 192 
can determine the overall period of exposure, but also because the metabolite(s), rather 193 
than the parent drug, may be responsible for the toxic effect [1,51].  In the non-mammalian 194 
area where much less is known about metabolic profiles of drugs in animals, in vivo 195 
experiments still have a major role to play to derive reliable environmental risk assessments 196 
[for case studies with freshwater fish see references 33,34,52] and also in wildlife forensic 197 
studies (see following case study on birds). 198 
 199 
 200 
 201 
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4.0 Case Study - Vulture toxicity to NSAIDs (A Process of Zero-Order Metabolism) 202 
 203 
The dramatic impact of diclofenac (a non-steroidal anti-inflammatory drug or ‘NSAID’) on 204 
Asian vulture populations represents one of the most serious ecological catastrophes of 205 
recent times.  In just over a decade, diclofenac has been responsible for the deaths of 206 
millions of vultures of the Asian White-backed (Gyps bengalensis), Long-Billed (G. indicus), 207 
Slender-billed (G. tenuirostris), Egyptian (Neophron percnopterus) and red-headed 208 
(Sarcogyps calvus) vulture species across the Indian subcontinent [53,54].  In addition to the 209 
scale of the toxicity, the exposure route to the product was probably highly unconventional 210 
as these birds were inadvertently being poisoned by the oral route even though diclofenac 211 
was only available as an injectable cattle formulation. Whereas previous veterinary 212 
medicines and pesticides had caused their negative effects by ending up in the water, soil or 213 
general environment of the species affected, these vultures were being exposed to this 214 
product as residues in the meat of the dead cattle carcasses upon which they fed. This 215 
unique mode of exposure was linked to cultural and religious practices in the region 216 
whereby sick and old cattle were routinely treated in a palliative manner with diclofenac, a 217 
cheap and effective NSAID. The net effect of this practice was an unfortunate high 218 
occurrence of diclofenac residues in the tissues of recently dead cattle.  219 
 220 
In the vulture, diclofenac is highly toxic with acute death resulting from a single meal of 1kg 221 
of meat rich in residue, with an estimated LD50 of 0.1 to 0.2 mg/kg [55]. Toxicity following 222 
exposure is also fairly predictable with birds showing signs of depression and head drooping 223 
as early as 24 hours post exposure. Death is the typical end-point with birds literally being 224 
described as falling dead from their perches. Based on the results from controlled toxicity 225 
studies, it has been shown that death after a single exposure consistently resulted within 48 226 
hours of exposure, with related massive increases in plasma uric acid and potassium 227 
concentrations and increased alkaline phosphatase (ALP) activity. Necropsies are also very 228 
typical with signs of severe nephrosis, dehydration and accompanying diffuse visceral and 229 
articular gout.   Histopathology indicated toxicity was characterised by necrosis of 230 
hepatocytes and the renal tubular epithelial cells (RTE) of the proximal convoluted tubules 231 
with associated uric acid tophi accumulation. While the mechanism of toxicity of diclofenac 232 
remains incompletely described, toxicity has been linked to RTE cell damage in a time 233 
related manner, subsequent accumulation of uric acid, acidosis and terminal hyperkalaemia 234 
[56].  Results from various pharmacokinetics studies of diclofenac in different bird species, 235 
and the pharmacokinetic profiles of ketoprofen and meloxicam in the vulture, clearly 236 
indicate that toxicity is related to the drug’s pharmacokinetics (Figure 1).   237 
 238 
Insert Figure 1 239 
 240 
For the first of these studies, the pharmacokinetics of diclofenac was evaluated in the Cape 241 
Griffon Vulture (Gyps coprotheres) [57]. While environmental toxicity has not been seen in 242 
this vulture, the species was specifically validated as a suitable model for further 243 
mechanistic studies on the toxicity of diclofenac and other NSAIDs. The choice of this 244 
species was two-fold, firstly the easier availability to the study site as well as being less 245 
endangered than the Indian vulture species. From this controlled acute toxicity study, the 246 
Cape Griffon was shown to be equally susceptible to diclofenac as the Oriental White-247 
backed at 0.8 mg/kg i.v. with exactly the same clinical signs, clinical pathological and 248 
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histopathological changes. Non-compartmental analysis revealed a half-life of elimination 249 
(T1/2) of 12.24 ± 0.99 hours, area under curve to the last quantifiable time point (AUClast) of 250 
80.28 ± 51.26 µg/ml/hour, a mean residence time (MRT) of 15.11 ± 4.13 hours.  To evaluate 251 
the importance of the obtained pharmacokinetic profile obtained, parameters were 252 
previously compared by [58] to that published for other bird species (Figure 2). This included 253 
the African-white backed vulture (G. africanus), the Pied crow (Corvus albus), the turkey 254 
vulture (Cathartes aura) and the domestic chicken (Gallus domesticus). For these studies no 255 
mortalities were reported for the Pied Crow (0.8 and 10mg/kg), Turkey Vulture (8 and 25 256 
mg/kg) and the domestic chicken (0.8 mg/kg), while toxicity was reported in the Cape 257 
Griffon (0.8 mg/kg), the African white-back (0.8 mg/kg) and one chicken at a higher dose (5 258 
mg/kg). An important finding from these comparisons was a tentative link between the T1/2 259 
and the occurrence of toxicity with a T1/2 above 12 hours being associated with death. 260 
Furthermore zero order metabolism was seen as a feature of toxicity as the T1/2 was 261 
increased in the one chicken that died, from 0.89 hours at 0.8 mg/kg to 14.34 hours at 5 262 
mg/kg. 263 
 264 
Insert Figure 2. 265 
 266 
While diclofenac has received wide attention in published literature as a result of its 267 
environmental toxic effect it is not, however, the only NSAID evaluated in vultures in terms 268 
of safety and pharmacokinetics.  In an attempt to have diclofenac removed from the Indian 269 
veterinary market, a replacement for the drug needed to be found for use in cattle, as 270 
diclofenac was of valuable cultural benefit to the sick cattle being treated. Following an 271 
international survey, meloxicam and ketoprofen were identified as potentially replacement 272 
i.e. they were effective in cattle with some evidence of safety in captive vulture species 273 
[59,60].  Subsequently both these drugs were evaluated in extensive safety studies including 274 
full characterisation of their pharmacokinetics once again in Cape Griffon as the model, with 275 
vastly contrasting results.  276 
 277 
In the first ketoprofen study Cape Griffon vultures treated at 1 mg/kg showed no indications 278 
of toxicity on both clinical and clinical pathological evaluations [61]. However, when a 279 
second group of vultures were treated at increased dose of 5 mg/kg, the study resulted in 280 
mortalities in seven of the 11 birds treated with the characteristic signs of toxicity seen in 281 
the diclofenac treated birds. The most interesting finding for this study was a difference in 282 
the T1/2 between these two dose levels but also between the birds that died or survived at 283 
the 5 mg/kg dose. At 1 mg/kg the half-life was 2.66 ± 0.46 hours. In the four birds that 284 
survived at 5 mg/kg the half-life was marginally higher at 3.24 ± 1.59 hours. For the birds 285 
that died at the 5 mg/kg dose, the half-life had increased to 7.38 ± 1.72 hours.  With regards 286 
to AUClast, the four birds that survived had an AUClast five-fold higher as expected for the 5-287 
fold increase in dose (9.79 ± 3.23 μg/ml/hour versus 50.31 ± 17.71 μg/ml/hour, respectively). 288 
However, the birds that died at 5 mg/kg had an increased AUClast of 156.51 ± 33.14 289 
μg/ml/hour and Cmax of 21.0 ± 1.88 μg/ml in comparison to 10.77 ± 3.26 μg/ml to the birds 290 
that survived. This once again supported previous findings that toxicity is related to zero 291 
order metabolism. In addition, the increase in the AUClast and Cmax also indicated that 292 
toxicity resulted in saturation of presystemic elimination pathways [61].  293 
 294 
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In the last of the described pharmacokinetic studies, meloxicam was administered to Cape 295 
Griffon vultures in a two-way cross over study at a dose of 2 mg/kg by either oral or 296 
intramuscular route, without any signs of toxicity or changes in the monitored clinical 297 
pathology parameters [59]. Meloxicam was characterised by a short half-life of elimination 298 
of 0.33 ± 0.167 hours and 0.42 ± 0.11 hours for the oral and intramuscular routes 299 
respectively. This study further attempted to characterise the metabolites produced via LC-300 
MSMS analysis. Two CYP metabolites, hydroxymethyl meloxicam (87%) and an unknown 301 
hydroxylated metabolite (7%), and one glucuronide (0.56%) metabolite were identified 302 
(Figure 3).  Based on literature in laboratory animals, it is suspected that the CYP most likely 303 
involved in metabolism was predominantly CYP2C9. 304 
 305 
Insert Figure 3. 306 
 307 
While the metabolic pathway for diclofenac in the vulture is yet to be evaluated, the current 308 
pharmacokinetic information available allows for some conclusions to be drawn. The first of 309 
these is that toxicity is clearly linked to zero order kinetics. For the NSAIDs, this deficiency 310 
could be at the level of the Phase I enzyme (CYP) system or Phase II glucuronidation, both of 311 
which have been previously described. Decreased CYP2C9 activity in people has been 312 
associated with resultant longer half-life of metabolised NSAIDs, while the absence of 313 
glucuronidation (UGT1A6) has been described as an important mechanism in the toxicity of 314 
paracetamol in the cat [18]. Limited glucuronide activity has also been described in people 315 
in association with aspirin toxicity. Based on the presence of a glucuronide metabolite for 316 
meloxicam, it is likely that toxicity in humans is not due to a complete absence of Phase II 317 
processes as in the cat. In addition, it is also doubtful that limited glucuronidation plays a 318 
role in human toxicity [62].  As a result, the rate limiting step in avian metabolism is most 319 
likely at the level of cytochrome P450 enzyme system. From medical literature, meloxicam is 320 
metabolised predominantly by the CYP2C9 and, to a much lower extent CYP3A4); diclofenac 321 
predominantly by the CYP2C9, with some metabolism by CYP3A4 and CYP2C8 [63,64]; and 322 
ketoprofen by CYP2C9 [65]. When the half-life of elimination of diclofenac, ketoprofen and 323 
meloxicam in people is compared to the vulture, an important difference is present. In 324 
humans the half-life of elimination of diclofenac, ketoprofen and meloxicam is typically 1-2 325 
hours, 2 hours and 15-20 hours, respectively [66], while as reported above this is ±14 hours, 326 
±3 hours and 0.33 hours, respectively for the vulture, with the metabolism of ketoprofen in 327 
vultures also being zero order.  With the CYP2C9 being the one common enzyme in 328 
metabolism, it is most probably that this is the rate limiting enzyme. With the rapid 329 
metabolism of meloxicam in vultures in contrast to humans, it may even be possible that 330 
the vulture is reliant on a Phase I system other than CYP2C9 for metabolism (in vultures 331 
CYP3A4 seem a possibility). If this is the case, then the extreme sensitivity of the vulture to 332 
NSAID toxicity may be associated with the hepatotoxicity of diclofenac in humans which is 333 
tentatively linked to CYP3A4 metabolism [67]. 334 
 335 
5.0 Conclusions 336 
 337 
Pharmaceuticals provide many important health and economic benefits in the context of 338 
their capacity to generate desired and specific therapeutic effects in the target species 339 
(namely humans or in some cases, domestic animals and companion animals).  In some 340 
cases, however, environmental exposures of wildlife to pharmaceutical residues can have 341 
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dramatic consequences on non-mammalian species, as seen in the case of diclofenac and 342 
vultures [54,55] or fish populations in ecosystems exposed to synthetic oestrogens [68].  343 
These notable examples, together with evidence of the widespread presence of 344 
pharmaceuticals in the environment, have been widely recognized to support the need for 345 
predictive environmental risk assessments [69-72] and consider API residues in cattle and 346 
other livestock species [73].   347 
 348 
A fundamental aspect of this challenge relates to the need to consider comparative 349 
metabolism for a range of non-mammalian species.  Specifically, it is clear that there remain 350 
major knowledge gaps regarding the comparative metabolisms of human and veterinary 351 
pharmaceuticals in non-mammalian species and this situation needs to be addressed in 352 
order to develop reliable environmental risk assessments for these important groups of 353 
medicines.  It is proposed that this knowledge gap could be addressed in an efficient and 354 
ethical manner through the use of in vitro methods to define metabolism of reference APIs 355 
(selected from Table 1) in hepatocytes from carnivorous birds compared with omnivorous 356 
bird species, for example cormorants Phalacrocorax auritus and chickens Gallus domesticus, 357 
respectively [74,75].  For fish, the same approach is feasible using in vitro hepatocyte assays 358 
for mainly carnivorous salmonid species such as rainbow trout (Oncorhynchus mykiss) 359 
versus the mainly herbivorous cyprinid species such as zebrafish (Danio rerio) or carp 360 
(Cyprinus carpio) [20, 25].  For invertebrates, an in vivo approach would seem the best 361 
option and should be extended to both freshwater and marine species as part of an Adverse 362 
Outcome Pathways approach [39, 76-78].  Subsequently, the in vitro avian and fish 363 
metabolic data and the in vivo invertebrate data for reference APIs could be used to develop 364 
and validate in silico tools to better predict which enzymes are responsible for API 365 
metabolism.  If the measured or predicted metabolism of a human or veterinary drug in 366 
mammalian or non-mammalian wildlife species raised concerns, further work could be done 367 
to evaluate the in vitro metabolites data through computational toxicology or metabolic 368 
pathway analysis [50, 79, 80].   369 
 370 
In the wider context, where predicted regional increases in drug use occur or measurements 371 
of APIs in the environment raise concerns, the availability of validated in silico and in vitro 372 
methods to predict comparative metabolism will be of immense use in conducting 373 
environmental risk assessments.  Specifically, together with prioritisation through the 374 
Predicted Exposure Concentration (PEC) approach, an understanding of ADMET can play an 375 
important role in defining Predicting No-Observed Effect Concentrations (PNECs) for 376 
freshwater, terrestrial and other environmental compartments, including predators 377 
[70,71,81].  In addition to this predictive aspect of pharmaceutical risk assessment, an 378 
understanding of ADMET can provide an important role for targeted monitoring of wildlife 379 
species of concern (eg vultures and other ultra-carnivorous species) [72,77]. 380 
   381 
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 637 
Figure 1. Estimated half-life of elimination for various avian species dosed with diclofenac in 638 
controlled toxicity studies. The half-lives have be ranked from fastest to slowest and 639 
represent; 1- Gallus domesticus (0.8 mg/kg); 2- Corvus albus (10 mg/kg); 3- Cathartes aura 640 
(25 mg/kg); 4- Cathartes aura (8 mg/kg); 5- Gyps coprotheres (0.8 mg/kg); 6-  Gallus 641 
domesticus (5mg/kg); 7- Gyps africanus (0.8 mg/kg). The red bars, indicate those doses 642 
associated with mortality. 643 
 644 
 645 
 646 
 647 
 648 
 649 
Figure 2.  Plasma versus time profiles for diclofenac at 0.8 mg/kg in the G. coprotheres  650 
(Rhomboid); ketoprofen at 5 mg/kg for the G. coprotheres that died (Square); ketoprofen at 651 
5 mg/kg in G. coprotheres that survived (Triangle); Diclofenac in chickens at 0.8 mg/kg (circle) 652 
and meloxicam in G. coprotheres at 2 mg/kg (cross).  653 
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 655 
 656 
 657 
Figure 3.  Relative response (AUC per peak on LC-MSMS chromatograms) versus time 658 
profiles for parent meloxicam and its three metabolites  hydroxymethyl meloxicam; an 659 
unidentified hydroxymethyl metabolite carboxymeloxicam and the glucuronide metabolite 660 
following treatment at 2 mg/kg in G. coprotheres. 661 
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Table 1.  Summary of vertebrate metabolic pathways with examples of pharmaceutical and 667 
xenobiotic substrates and inhibitors. 668 
Enzyme Localization Substrate Inhibitor 
Phase I – Hydrolysis Reactions: 
Esterase Microsomes, cytosol trandolapril tamoxifen 
Peptidase Lysosomes - alogliptin 
Epoxide hydrolase Microsomes, cytosol Diazepam valproate 
Phase I – Reduction Reactions: 
Azo- and nitro-reduction Microsomes, cytosol Prontosil clofibrate 
Carbonyl reduction Microsomes, cytosol Loxoprofen befunolol 
Disulphide reduction Cytosol captopril - 
Sulphoxide reduction Cytosol - dimethylsulfoxide 
Quinone reduction Microsomes, cytosol Trenimon  warfarin 
Reductive 
dehalogenation 
Microsomes Chloramphenicol - 
Phase I – Oxidation Reactions: 
Alcohol dehydrogenase Cytosol ethanol fomepizole 
Aldehyde dehydrogenase Mitochondria, cytosol acetaldehyde disulfiram 
Aldehyde oxidase Cytosol Aldehyde raloxifene 
Xanthine oxidase Cytosol xanthine allopurinol 
Monoamine oxidase Mitochondria Monoamine moclobemide 
Diamine oxidase Cytosol diamine phenformin 
Prostaglandin H synthase Microsomes arachidonic acid ibuprofen 
Flavin-monooxygenases Microsomes riboflavin nitric oxide 
Cytochrome P450: Microsomes - - 
CYP1A1 Microsomes 7-ethoyxyresorufin galangin 
CYP1A2 Microsomes clozapine 
propranolol 
cimetidine 
citalopram 
CYP2C19 Microsomes citalopram 
diazepam 
fluoxetine 
ketoconazole 
CYP2C9 Microsomes diclofenac 
ibuprofen 
fluconazole 
fluoxetine 
CYP2D6 Microsomes metoprolol 
tramadol 
fluoxetine 
sertraline 
CYP2E1 Microsomes acetaminophen 
ethanol 
disulfiram  
water cress 
CYP3A4 Microsomes carbamazepine 
simvastatin 
flavonoids 
ketoconazole 
Phase II – Enzyme Reactions: 
Glucuronide conjugation Microsomes Phase I metabolites valproic acid 
Sulphate conjugation Cytostol Phase I metabolites harmol 
Glutathione conjugation Microsomes, cytosol Phase I metabolites tannic acid 
Amino acid conjugation Microsome Phase I metabolites kinetin 
Acetylation Mitochondria, cytosol Phase I metabolites garcinol 
Methylation Microsomes, cytosol Phase I metabolites 5-A-2′deoxycytidine 
 669 
Table 1 = 220 words  670 
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Table 2.  Representative examples of computational tools for predicting factors associated 671 
with mammalian metabolism (note - programs may have additional capabilities). 672 
Factor 
Predicted 
Software Summary of method Website or key citation 
(i) Site of 
metabolism 
Metaprint2D Predicts sites of Phase I 
metabolism in dog, human and rat 
through data-mining and statistical 
analysis of published metabolic 
transformations. 
http://www-
metaprint2d.ch.cam.ac.
uk/metaprint2d 
(ii) Potential 
Metabolites 
Meteor Nexus Uses expert knowledge rules for 
metabolism to predict metabolites 
which are presented in metabolic 
trees 
http://www.lhasalimite
d.org/products/meteor
-nexus.htm 
(iii) CYP 
binding 
affinity / 
inhibition 
isoCYP Predicts the predominant human 
cytochrome P450 isoform by which 
a compound is metabolised 
http://www.molecular-
networks.com/product
s/isocyp 
(iv) CYP 
induction 
VirtualToxLab Predicts binding affinities to Aryl 
hydrocarbon receptor (and other 
targets) using flexible docking and 
quantitative structure-activity 
relationships 
http://www.biograf.ch/
index.php?id=projects
&subid=virtualtoxlab 
 673 
Table 2 = 121 words 674 
 675 
